# Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

> **NCT00074269** · PHASE2 · TERMINATED · sponsor: **University of California, San Diego** · enrollment: 5 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** graft-versus-tumor induction therapy
- **BIOLOGICAL:** therapeutic allogeneic lymphocytes
- **DRUG:** cyclosporine
- **DRUG:** fludarabine phosphate
- **DRUG:** melphalan
- **DRUG:** methotrexate
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00074269
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-07
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Terminated early due to poor enrollment
- **Last updated:** 2023-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074269, "Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00074269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*